Cancer Chemotherapy and Pharmacology

, Volume 30, Issue 1, pp 1–6

A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy

Authors

  • Tetsu Shinkai
    • Department of Medical OncologyNational Cancer Center Hospital
  • Kenji Eguchi
    • Department of Medical OncologyNational Cancer Center Hospital
  • Yasutsuna Sasaki
    • Department of Medical OncologyNational Cancer Center Hospital
  • Tomohide Tamura
    • Department of Medical OncologyNational Cancer Center Hospital
  • Yuichiro Ohe
    • Department of Medical OncologyNational Cancer Center Hospital
  • Akira Kojima
    • Department of Medical OncologyNational Cancer Center Hospital
  • Fumihiro Oshita
    • Department of Medical OncologyNational Cancer Center Hospital
  • Toshimichi Miya
    • Department of Medical OncologyNational Cancer Center Hospital
  • Hiroaki Okamoto
    • Department of Medical OncologyNational Cancer Center Hospital
  • Kazuchiyo Iemura
    • Department of Medical OncologyNational Cancer Center Hospital
  • Nagahiro Saijo
    • Department of Medical OncologyNational Cancer Center Hospital
    • Pharmacology DivisionNational Cancer Center Research Institute
Original Articles Prognostic Factor, Chemotherapy, Non-small Cell Lung Cancer

DOI: 10.1007/BF00686477

Cite this article as:
Shinkai, T., Eguchi, K., Sasaki, Y. et al. Cancer Chemother. Pharmacol. (1992) 30: 1. doi:10.1007/BF00686477

Summary

Prognostic factors for response and survival were retrospectively evaluated in 192 previously untreated patients with advanced non-small-cell lung cancer (NSCLC) who had received either vindesine plus cisplatin or mitomycin plus vindesine plus cisplatin as initial treatment. Univariate analysis demonstrated that squamous-cell histology, early stage, and a small number of metastatic sites were favorable prognostic factors for response to chemotherapy. Multivariate analysis using Cox's proportional hazard model indicated that the number of metastatic sites was the only significant pretreatment factor for response (P=0.0005). Multivariate regression analysis revealed that the number of metastatic sites (P=0.0002), sex (P=0.0009), serum albumen levels (P=0.0018), performance status (P=0.0026) and lactic dehydrogenase values (P=0.0026) contributed independently to survival. On the basis of these five prognostic factors, a prognostic index for survival was used to define three prognostic groupings (good, intermediate, and poor) for survival (median survival, 16.5 vs 9.4 vs 4.6 months;P=0.0001). This particular regression model should aid in the design and analysis of new treatment strategies and may be useful for indirect comparisons of different studies carried out in similar patient populations.

Copyright information

© Springer-Verlag 1992